RESEARCH 研究の報告

2024.3.15

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).

著者 Nakamichi S, Kubota K, Misumi T, Kondo T, Murakami S, Shiraishi Y, Imai H, Harada D, Isobe K, Itani H, Takata S, Wakui H, Misumi Y, Ikeda S, Asao T, Furuya N, Hosokawa S, Kobayashi Y, Takiguchi Y, Okamoto H.

Clin Cancer Res. 2024 Mar 15;30(6):1104-1110. doi: 10.1158/1078-0432.CCR-23-2568.

PMID: 38165684 Free PMC article. Clinical Trial.

2024.3.9

Small cell lung carcinoma initially presenting as giant left ventricular mass.

著者 Yamaguchi O, Kaira K, Imai H, Kagamu H.

Jpn J Clin Oncol. 2024 Mar 9;54(3):359-360. doi: 10.1093/jjco/hyad173.

PMID: 38088026 No abstract available.

2024.3.1

Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.

著者 Kaira K, Imai H, Kagamu H.

Lung Cancer. 2024 Mar;189:107501. doi: 10.1016/j.lungcan.2024.107501. Epub 2024 Feb 9.

PMID: 38342048 No abstract available.

2024.2.20

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.

著者 Tozuka T, Minegishi Y, Yamaguchi O, Watanabe K, Toi Y, Saito R, Nagai Y, Tamura Y, Shoji T, Odagiri H, Ebi N, Sakai K, Kanaji N, Izumi M, Soda S, Watanabe S, Morita S, Kobayashi K, Seike M.

JTO Clin Res Rep. 2024 Feb 20;5(4):100655. doi: 10.1016/j.jtocrr.2024.100655.

PMID: 38706978; PMCID: PMC11069015.

2024.2.1

Osimertinib with Chemotherapy in EGFR- Mutated NSCLC. Reply.

著者 Planchard D, Jänne PA, Kobayashi K.

N Engl J Med. 2024 Feb 1;390(5):478-479. doi: 10.1056/NEJMc2314600.

PMID: 38294984.

2024.2.1

Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.

著者 Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Kawasaki T, Kobayashi K, Imai H, Kagamu H.

Int J Clin Oncol. 2024 Feb;29(2):124-133. doi: 10.1007/s10147-023-02445-4. Epub 2023 Dec 31.

PMID: 38160406

2024.1.19

Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.

著者 Ito K, Hashimoto K, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Imai H, Kuji I, Kagamu H.

Oncol Lett. 2024 Jan 19;27(3):110. doi: 10.3892/ol.2024.14243. eCollection 2024 Mar.

PMID: 38304175 Free PMC article.

2024.1.10

Risk Factors for Bleeding Events in Japanese Patients with Advanced Lung Cancer: Data from the Rising-VTE/NEJ037 Study.

著者 Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T.

Cancers (Basel). 2024 Jan 10;16(2):301. doi: 10.3390/cancers16020301.

PMID: 38254791; PMCID: PMC10814048.